Upstream Bio【UPB】銘柄情報

Upstream Bio Inc (UPB) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

7.51

( 3.16% )

買値

4.65

売値

9.37

出来高

363,221

7.1636 日の範囲 7.72

5.85 52 週間の範囲 33.68

時価総額

408.694M

前日終値

7.28

始値

7.31

時刻

7.51

最終取引時間

財務取引量

US$ 2,696,356

VWAP

7.4235

平均取引量 (3 か月)

US$ 606,616

発行済株式数

54,419,986

配当利回り

PER

-2.51

1 株当たり利益 (EPS)

-2.9

歳入

3.32M

純利益

-156.76M

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive ... Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

upstreambio.com

本社

Waltham, United States

設立

2026

Upstream Bio Inc is listed in the Healthcare sector of the ナスダック市場 with ticker UPB. The last closing price for Upstream Bio was US$7.28. Over the last year, Upstream Bio shares have traded in a share price range of US$ 5.85 to US$ 33.68.

Upstream Bio currently has 54,419,986 shares in issue. The market capitalisation of Upstream Bio is US$408.69 million. Upstream Bio has a price to earnings ratio (PE ratio) of -2.51.

Form 4 - Statement of changes in beneficial ownership of securities

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company...

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company...

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	1.19	18.8291139241	6.32	7.51	6.28	710692	6.84235639	CS
4	-0.17	-2.21354166667	7.68	7.78	5.85	732231	6.50393924	CS
12	-2.16	-22.3371251293	9.67	10.6676	5.85	616471	8.10407271	CS
26	-19.79	-72.4908424908	27.3	33.68	5.85	928881	12.08622643	CS
52	-3.28	-30.3985171455	10.79	33.68	5.85	695915	15.00125404	CS
156	-13.99	-65.0697674419	21.5	33.68	5.14	547987	14.59684509	CS
260	-13.99	-65.0697674419	21.5	33.68	5.14	547987	14.59684509	CS